Dopamine agonists are usually very effective in the treatment of prolactinomas.
Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this …

Background Dopamine agonist resistance in prolactinoma is an infrequent phenomenon.
Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling …

Abstract Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was
shown to be effective in tumoral hyperprolactinemia. The aim of this study was to investigate …

Resistance to dopamine agonists is defined here as failure to normalize prolactin levels and
failure to decrease macroprolactinoma size by≥ 50%. Failure to normalize prolactin levels …

Context Macroprolactinomas poorly responsive to dopamine-agonists are often more
aggressive and are usually termed 'resistant'but this clinical concept has always been …

Resistance to dopamine agonists can be defined with respect to failure to normalize PRL
levels and failure to decrease tumor size by≥ 50%. Using these definitions, failure to …

The authors' object in this paper was to review the definition, epidemiology, biology,
resistance mechanisms, and treatment options for dopamine agonist–resistant …

Surgery for prolactinoma patients is usually reserved for those who are intolerant of or have
an inadequate response to medication. We report the results of surgical treatment in these …

Prolactinomas are the most common hormone-secreting pituitary tumours and cause
infertility and gonadal and sexual dysfunction in both sexes. The approach to prolactinomas …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …